Growth Metrics

Rapid Micro Biosystems (RPID) Debt to Equity (2020 - 2026)

Rapid Micro Biosystems recorded quarterly Debt to Equity of $0.93 in Q1 2026, up 64.09% quarter-over-quarter from $0.57 in Q4 2025.

Rapid Micro Biosystems' Debt to Equity history runs 4 years deep, the most recent figure standing at $0.93 for Q1 2026.

  • In Q1 2026, Debt to Equity changed N/A year-over-year to $0.93; the TTM figure through Mar 2026 stood at $0.93 (changed N/A YoY), while the FY2025 annual figure was $0.57, changed N/A from the prior year.
  • Debt to Equity came in at $0.93 for Q1 2026 at Rapid Micro Biosystems, up from $0.57 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.93 in Q1 2026 to a low of $0.42 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.65
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 0.64
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.57
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.42
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.06
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.95
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 0.27
10 Rapid Micro Biosystems 89.50 Mn 66.56 Mn 371,000.00 0.93

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.93
Dec 31, 2025 0.57
Sep 30, 2025 0.42
Jun 30, 2021 -0.15
Dec 31, 2020 -0.20